

**A post-doctoral fellowship position (2 years) is available
in the group of Jean-Louis Herrmann in the Inserm/UVSQ Team EPIM
(UFR Sciences de la Santé Simone Veil, Montigny le Bretonneux)
Starting First semester 2022**

Project: *Mycobacterium abscessus* is a rapidly growing mycobacterium increasingly acknowledged as a serious non-tuberculous mycobacterial pathogen. Recent studies indicate that complex lipids unique to *M. abscessus* can act as potent immuno-modulators, playing key roles in virulence and conditioning the outcome of the infection. *M. abscessus*, therefore, represents a biologically relevant species for the discovery of new lipids which, together with the elucidation of their biosynthetic/transport pathways, would further enlighten cell wall assembly and allow appreciation for how these unique lipids benefit mycobacteria to manipulate the host response. Our consortium, funded by the National Research Agency, is made of four specialized research partners in mycobacteriology, bacterial genetics, lipid biochemistry and cell biology. In strong partnership with these teams, the selected candidate will *i)* generate and study the phenotypes of lipid-defective *M. abscessus* mutant strains, *ii)* analyze the contribution of these lipids in *M. abscessus* virulence in macrophages and animal models (ZF and mice), *iii)* investigate the ability of the purified lipids to modulate the early host response.

Candidate: We are seeking a highly motivated and hard-working candidate with a strong background in mycobacterial genetics and/or in eukaryotic cells and animal manipulations who is interested in working in a dynamic group environment. We offer a rich multidisciplinary environment, as well as access to different experimental approaches through our labs and core facilities to ensure the successful development of the research.

Application:

Interested candidates should send a CV including a list of publications, a letter of motivation and the names of 2-3 potential references to Jean-Louis Herrmann (jean-louis.herrmann@uvsq.fr)

[Infection et inflammation \(2i\) - UVSQ](https://www.2i.uvsq.fr)

<https://www.2i.uvsq.fr>

<https://www.2i.uvsq.fr/equipe-3-epim>

Related publications from the lab:

- Le Moigne V, et al. Vaccine. 2015 Apr 27;33(18):2118-24. doi: 10.1016/j.vaccine.2015.03.030.
- Bernut A, et al. Mol Microbiol. 2016. 99: 866-83.
- Roux AL, et al. Open Biol. 2016. 6(11) pii: 16018.
- Laencina L et al. Proc Natl Acad Sci U S A. 2018. 115: E1002-E1011.
- Dubois V, et al. Proc Natl Acad Sci U S A. 2018 Oct 9. pii: 201812984. doi: 10.1073/pnas.1812984115.
- Dubois et al., PLoS Pathog. 2019 Nov 8;15(11):e1008069. doi: 10.1371/journal.ppat.1008069.
- Johansen et al., Nat Rev Microbiol, 2020 Jul;18(7):392-407. doi: 10.1038/s41579-020-0331-1.
- Le Moigne V et al., Antimicrob Agents Chemother. 2020 May 21;64(6):e00114-20. doi: 10.1128/AAC.00114-20.
- Le Moigne V et al., Front Cell Infect Microbiol. 2020 Aug 27;10:432. doi: 10.3389/fcimb.2020.00432.
- Lagune et al., Microbiology (Reading). 2021 Jul;167(7). doi: 10.1099/mic.0.001054.
- Chalmers et al., Eur Respir Rev. 2021 Jul 20;30(161):210010. doi: 10.1183/16000617.0010-2021.
- Le Moigne et al., J Cyst Fibros. 2021 Sep 9:S1569-1993(21)01360-6. doi: 10.1016/j.jcf.2021.08.019.